

Accepted Manuscript

Brief Report: Acquired resistance to first-line Afatinib and the challenges of pre-arranged progression biopsies

Meghan Campo, David Gerber, Justin F. Gainor, Rebecca S. Heist, Jennifer S. Temel, Alice T. Shaw, Panos Fidias, Alona Muzikansky, Jeffrey A. Engelman, Lecia V. Sequist, M.D., M.P.H

PII: S1556-0864(16)30846-2

DOI: [10.1016/j.jtho.2016.06.032](https://doi.org/10.1016/j.jtho.2016.06.032)

Reference: JTHO 314

To appear in: *Journal of Thoracic Oncology*

Received Date: 20 April 2016

Revised Date: 17 June 2016

Accepted Date: 24 June 2016

Please cite this article as: Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV, Brief Report: Acquired resistance to first-line Afatinib and the challenges of pre-arranged progression biopsies, *Journal of Thoracic Oncology* (2016), doi: 10.1016/j.jtho.2016.06.032.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Brief Report: Acquired resistance to first-line Afatinib and the challenges of pre-arranged progression biopsies.

Meghan Campo¹, David Gerber², Justin F. Gainor¹, Rebecca S. Heist¹, Jennifer S. Temel¹, Alice T. Shaw¹, Panos Fidias¹, Alona Muzikansky¹, Jeffrey A. Engelman¹, and Lecia V. Sequist¹

1. Massachusetts General Hospital and Harvard Medical School, Boston, MA. 2. University of Texas Southwestern Medical School, Dallas, TX.

Corresponding Author

Lecia V. Sequist, M.D., M.P.H.
32 Fruit Street, Yawkey 7B
Boston MA, 02114-2696
Fax: 617-724-3166
Telephone: 617-724-4000
Email: lvsequist@partners.org

Support:

Boehringer-Ingelheim Pharmaceuticals, Inc.

Disclosures:

Meghan Campo has nothing to disclose.

David Gerber has nothing to disclose.

Justin F. Gainor reports personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Merck, personal fees from Bristol-Myers Squibb, personal fees from Genentech, non-financial support from Jounce, personal fees from Kyowa Hakko Kirin, outside the submitted work; .

Rebecca S. Heist reports consulting honoraria from Boehringer Ingelheim, and Ariad outside the submitted work.

Jennifer S. Temel has nothing to disclose.

Alice T. Shaw reports personal fees from Pfizer, personal fees from Genentech, during the conduct of the study; personal fees from Novartis, personal fees from Roche, personal fees from Ariad, personal fees from Daiichi-sankyo, personal fees from Taiho, personal fees from EMD Serono, personal fees from Blueprint medicine, personal fees from Ignyta, outside the submitted work; .

Panos Fidias reports personal fees from Boehringer-Ingelheim, outside the submitted work; .

Alona Muzikanskym has nothing to disclose.

Jeffrey A. Engelman reports grants, personal fees and non-financial support from Sanofi Aventis, grants, personal fees, non-financial support and other from Novartis, personal fees and non-financial support from Genentech, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Amgen, personal fees and non-financial support from Clovis, grants, personal fees and non-financial support from Astra Zeneca, other from Gatekeeper, outside the submitted work; In addition, Dr. Engelman has a patent Methods for Treating Cancer Resistant to ErbB Therapeutics licensed to Ventana .

Download English Version:

<https://daneshyari.com/en/article/5701801>

Download Persian Version:

<https://daneshyari.com/article/5701801>

[Daneshyari.com](https://daneshyari.com)